UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038890
Receipt number R000044341
Scientific Title Study of complications and disease developed after vitrectomy
Date of disclosure of the study information 2019/12/21
Last modified on 2019/12/15 14:46:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of complications and disease developed after vitrectomy

Acronym

Study of complications and disease developed after vitrectomy

Scientific Title

Study of complications and disease developed after vitrectomy

Scientific Title:Acronym

Study of disease developed after vitrectomy

Region

Japan


Condition

Condition

retinal detachment, epiretinal membrane, macular hole, diabetic retinopathy, proliferative vitreoretiopathy, retinal vein occlusion.

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Purpose and significance of research (outline)
The purpose of this study is to analyze cases of disease after vitrectomy. Our university has one of the largest number of vitreous surgery cases in the country, and the data is managed as a database. However, vitreous surgery always has the risk of not being able to improve visual function due to post-operative complications and post-surgical diseases, and there is currently no knowledge about the risk factors. Therefore, in this study, we will retrospectively examine cases in which postoperative disease has occurred among the cases that have undergone vitreous surgery.

Basic objectives2

Others

Basic objectives -Others

To investigate the onset rate and the risk factors, progression of epiretinal membrane and macular hole after Rhegmatogenous retinal detachment.

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

At pre operation and one year after post operation
Medical history, treatment history, occurrence of side effects, visual acuity, intraocular pressure, surgical articles, laser flare cell meter, OCT image, OPTOS image, and other ophthalmic examination items.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

all patients underwent vitrectomy in our hospital
from January 2008 to Jun 2019.

Key exclusion criteria

Patients underwent vitrectomy before. Not primary vitrectomy cases.

Target sample size

3200


Research contact person

Name of lead principal investigator

1st name Masayuki
Middle name
Last name Horiguchi

Organization

Fujita Health University of Medicine.

Division name

ophthalmology

Zip code

4701192

Address

1-98, Dengakugakubo, Kutukake-cho, Toyoake city, Aichi prefecture, Japan.

TEL

0562932097

Email

masayuki@fujita-hu.ac.jp


Public contact

Name of contact person

1st name Tadashi
Middle name
Last name Mizuguchi

Organization

Fujita Health University of Medicine.

Division name

ophthalmology

Zip code

4701192

Address

1-98, Dengakugakubo, Kutukake-cho, Toyoake city, Aichi prefecture, Japan.

TEL

0562932097

Homepage URL


Email

mizu@fujita-hu.ac.jp


Sponsor or person

Institute

Fujita Health University of Medicine.

Institute

Department

Personal name



Funding Source

Organization

Fujita Health University of Medicine.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

study support promotion office.

Address

1-98, Dengakugakubo, Kutukake-cho, Toyoake city, Aichi prefecture, Japan.

Tel

0562932862

Email

kenshien@fujita-hu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

藤田医科大学病院


Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 10 Month 01 Day

Date of IRB

2019 Year 10 Month 16 Day

Anticipated trial start date

2019 Year 10 Month 16 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry

2024 Year 12 Month 31 Day

Date trial data considered complete

2024 Year 12 Month 31 Day

Date analysis concluded

2025 Year 12 Month 31 Day


Other

Other related information

Participants and method
Among the 3548 eyes, a traction component that causes RD (proliferative diabetic diabetic), which was performed for the repair of RRD from 1 January 2008 to 28 February 2019 at Fujita Medical University Hospital History of retinopathy and proliferative vitreoretinopathy, BRVO, trauma, etc., previous RD surgery including MHRD, giant tear RRD, buckling, PPV with buckling, encircling, choroid detachment, and PPV with silicone oil tamponade Patients were excluded (2954 eyes). Of the 2954 eyes (2520), vitrectomy 2455 eyes (person) and buckle 499 eyes (469). We review the electronic medical records retrospectively for 1737 eyes (1697 patients) excluding vitrectomy2455 eyes, preoperative OCT, 117 eyes with ERM, 514 eyes that cannot be judged by OCT, and 87 eyes without preoperative OCT.
Use ophthalmoscopic fundus findings, fundus photography, and optical coherence tomography (OCT) to define ERM.
Six judges judged whether there was ERM by interpreting randomly assigned medical records, OCT images, and fundus photographs. If in doubt, the two persons in charge of interpretation interpret the results and adopt the matching results. Excluded are those that have not been OCT preoperatively, those that cannot be judged due to opacity of the intermediate translucent body due to vitreous hemorrhage, etc. To do.
Factors that required ERM removal surgery (ERM group) and those that did not require ERM surgery (non-ERM group) due to ERM formation after only PPV for initial RRD repair Compare and consider. Furthermore, we investigate the incidence of ERM peeling surgery and changes in corrected visual acuity before and after ERM surgery.


Management information

Registered date

2019 Year 12 Month 15 Day

Last modified on

2019 Year 12 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044341


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name